UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 18, 2005
ARIAD Pharmaceuticals, Inc.
- -------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-21696 22-3106987
- -------------------------------------------------------------------------------
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
26 Landsdowne Street, Cambridge, Massachusetts 02139
- -------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (617) 494-0400
Not Applicable
- -------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 8.01 Other Events.
On August 18, 2005, ARIAD Pharmaceuticals, Inc. (the "Company") issued a press
release announcing that AP23573, its novel mTOR inhibitor, has been designated
an orphan drug by the United States Food and Drug Administration (FDA) for the
treatment of both soft-tissue and bone sarcomas. The information contained in
the press release dated August 18, 2005, is incorporated herein by reference and
attached to this Current Report on Form 8-K as Exhibit 99.1 hereto.
ITEM 9.01 Financial Statements and Exhibits.
(c) The following exhibits are filed with this report
Exhibit
Number Description
-------- -----------------------------------------------------
99.1 The Registrant's press release dated August 18, 2005.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ARIAD Pharmaceuticals, Inc.
By: /s/ Edward M. Fitzgerald
-----------------------------------------
Edward M. Fitzgerald
Senior Vice President and
Chief Financial Officer
Date: August 18, 2005
EXHIBIT INDEX
Exhibit
Number Description
- -------- -----------
99.1 The Registrant's press release dated August 18, 2005.